AGP Executive Report
Last update: 6 hours agoMedical AI & Diagnostics: BlinkLab reported positive European ADHD trial results for its smartphone-based Dx2, with 82% sensitivity and 83% specificity in a Netherlands-led multicentre cohort, and says it will now prepare a US regulatory study. Healthcare Robotics: Vitestro’s autonomous phlebotomy system Aletta is backed by a Netherlands multicentre trial published in Clinical Chemistry, aiming to ease staffing shortages by automating vein finding and blood draw. Alzheimer’s Immunotherapy: A Phase 1b trial cleared IBC-Ab002 (anti-PD-L1) as safe in early Alzheimer’s, with reported shifts in neurodegenerative biomarkers and a systemic immune “rejuvenation” approach. AI Investment in Europe: European AI startups raised a record $23B in H1 2026, taking 55% of regional VC, with funding concentrated in a small set of breakout companies. Cybersecurity & Privacy: A peer review ranks MI6 top in Europe, while Liechtenstein disclosed a cyberattack on a beneficial ownership register—raising questions about transparency vs. security. Energy & Environment: Rotterdam’s oyster-reef restoration pilot uses remote-setting methods to seed young oysters at sea, and satellite work flags hidden carbon emissions from oil and gas sites, including unrecorded mining sources. Dutch Tech & Industry: Ore Energy’s iron-air battery push continues with new funding, and Dutch drought impacts the Rhine, disrupting shipping and water supplies.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.